This page is written for parents and caregivers, because the internet’s teen-GLP-1 content splits between panic and promotion and almost none of it answers the questions families actually have: what’s approved, what the pediatric trial really showed, what the pediatricians’ own guideline says, what remains unknown — and where a decision like this should be made. That last one has the clearest answer of all, so it gets the ending.
The approval map, precisely
Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management from age 12, on the strength of a dedicated adolescent trial, joining liraglutide (Saxenda), which reached the same age band earlier with more modest results. Tirzepatide (Zepbound) is not approved for anyone under 18 — adolescent trials are underway, and until they read out, teen tirzepatide has no approved basis. Nothing compounded changes any of this; more on that below.
What STEP TEENS actually showed
The pivotal trial (Weghuber and colleagues, NEJM 2022) randomized 12-to-17-year-olds with obesity to weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention, for 68 weeks. Results: about a 16% average reduction in BMI on semaglutide versus roughly a 0.6% increase on placebo — an effect size comparable to, even exceeding, the adult trials, with about three-quarters of treated teens achieving ≥5% BMI reduction. Side effects mirrored the adult profile — gastrointestinal, front-loaded, mostly manageable — with no new pediatric-specific safety signal within the trial’s window and no observed impairment of growth in that timeframe. Honest limits: 68 weeks is a season of adolescence, not a follow-up into adulthood, and the trial’s few hundred participants can’t detect rare harms. Efficacy is established; the long horizon is not.
What the pediatricians’ guideline says
The American Academy of Pediatrics’ 2023 clinical practice guideline — its first comprehensive obesity guideline in fifteen years — recommends that clinicians offer adolescents 12 and older with obesity weight-loss pharmacotherapy as an adjunct to intensive health-behavior and lifestyle treatment, according to indications and risks. Two things are true about that sentence: it is a real, evidence-graded endorsement of medication as part of pediatric obesity care, reflecting the guideline’s core claim that obesity is a chronic disease rather than a willpower deficit — and it generated genuine professional controversy, with critics raising eating-disorder risks, medicalization concerns, and the long-term-data gap. Families deserve to know both halves: the mainstream pediatric position supports the option; the option remains debated at its edges.
The legitimate concerns, stated fairly
Four survive scrutiny. Duration: obesity is chronic and regain follows discontinuation, so a 14-year-old starting therapy is plausibly beginning a decades-long course — a commitment no 68-week trial can fully underwrite, particularly through puberty’s growth, bone-accrual, and hormonal milestones, where longer-term study is simply pending. Nutrition: an appetite-suppressed adolescent still has to build an adult skeleton and body — protein, calcium, and micronutrient adequacy (the adult playbook is here) matter even more before growth plates close, which is one reason real programs embed dietitians. Eating-disorder screening — in both directions: adolescents with obesity carry elevated rates of disordered eating, appetite-suppressing medication in a vulnerable teen requires screening before and monitoring during, and simultaneously the guideline authors’ counterpoint is also true — untreated obesity itself drives disordered eating and profound psychosocial harm. This is precisely the trade-off a specialist, not a checkout page, should weigh. And the unknown unknowns: rare or slow harms only surveillance will reveal, which is an argument for treating within systems that actually conduct it.
Why compounded is a hard no for minors
Adults reading this site can weigh compounded products’ trade-offs — unapproved but legal-in-context, cheaper, quality-variable — as informed consumers of a contested market. A minor cannot, and shouldn’t have to: no pediatric dosing standardization, no approved pediatric basis, concentration-dependent syringe math with a child’s smaller margin for error, and zero pediatric safety surveillance. Every professional voice in this space lands the same place we do — if a GLP-1 is ever right for a teenager, it is the FDA-approved product, at the approved age, or it is nothing.
The venue question — the one that settles most others
Here is where this site argues against its own category. Direct-to-consumer telehealth — the industry we review — is built for adults: the platforms in our files are 18-plus by their own terms, and that’s correct. Pediatric obesity pharmacotherapy belongs in pediatric hands: a pediatrician or pediatric obesity-medicine program that measures growth against curves, screens for eating disorders properly, involves the family in the lifestyle treatment the guideline pairs with any prescription, and follows the patient for years — in person. If you encounter any online service willing to ship a minor GLP-1 therapy on a questionnaire, you have not found convenient care; you have found the strongest possible signal to leave. That single fact — the right venue is a pediatric clinic, not a website — answers most of the practical questions families bring to this page.
Insurance and access, briefly
Coverage for adolescent Wegovy exists but is inconsistent — pediatric indication notwithstanding, the same employer-plan exclusions mapped in the coverage file apply, prior authorization is near-universal, and manufacturer savings programs have eligibility limits families should verify directly. A pediatric obesity clinic’s staff typically navigates this paperwork daily — one more argument for the venue.
Questions for the pediatrician
Does my teen meet the guideline’s criteria, and what does the intensive lifestyle component look like for our family? Who screens for disordered eating, and how often? How will growth, bones, and nutrition be monitored? What’s the plan’s time horizon — and its off-ramp? And would we be treating the health problem, or the mirror’s — a question worth asking out loud, because the answer shapes everything.
The bottom line
Approved from 12 (semaglutide, not tirzepatide), impressively effective in its trial, endorsed-with-conditions by the pediatricians’ own guideline, genuinely uncertain over the long horizon, and absolutely not a DTC or compounded product. For families, the decision is real but the door is specific: a pediatric clinician who treats the whole kid — growth curves, psychology, family, and all — or no prescription at all.
What a real pediatric visit looks like
Families deserve a preview so the good version is recognizable. Expect: growth-curve and BMI-percentile review across years, not a single weigh-in; baseline labs; explicit screening conversations about eating patterns, body image, and mood; enrollment in — or referral to — the intensive lifestyle program the guideline pairs with any prescription, involving the household’s food and activity environment, not just the teen’s willpower; and, if medication is chosen, a titration plan with scheduled follow-ups measuring growth and nutrition alongside weight. The whole apparatus is the treatment; the injection is one component. Any pathway offering the component without the apparatus — online or off — is selling a part as the machine.
The almost-18 edge case
A 17-and-a-half-year-old sits months from the adult DTC market, and some families are tempted to simply wait out the birthday. Legally, that works; clinically, nothing changes at midnight — growth, bone accrual, and the value of eating-disorder-aware monitoring extend well past 18, and the pediatric-or-specialist venue remains the better answer through the late-teen years even once adult platforms will say yes. The birthday changes who may prescribe, not who should.
The mirror question, named out loud
Teenagers marinate in the same GLP-1 culture adults do, minus the filters — and some requests for “the shot” are health-driven while others are appearance-driven distress wearing medical language. The guideline’s criteria (obesity by pediatric definitions, comorbidities, failed structured lifestyle treatment) exist partly to separate those — and a clinic that screens body image is protecting your kid in both directions: from untreated disease and from medicalizing a mirror problem. Parents can ask the question directly; the answer, either way, is information the right clinician wants.
Two questions families ask
Is Saxenda “safer” because it’s older? Not meaningfully — it’s a daily injection with clearly weaker adolescent results; STEP TEENS is why semaglutide leads the conversation, and “older” isn’t a safety category. What if our pediatrician refuses to discuss any of this? Blanket refusal-on-principle and questionnaire-prescribing are mirror-image failures of the same duty. The move is a second opinion from pediatric obesity medicine or pediatric endocrinology — clinicians who engage the evidence, criteria, and your specific kid, and who are just as willing to say “not this one, not yet.”
One line for the teen reading this
If you found this page yourself: good — it means you take your health seriously, and that instinct is right even where the internet’s answers aren’t. The honest summary is that this decision genuinely can’t be made well through a website — ours included — because the medicine only works safely inside real care: a clinician who knows your growth charts, your labs, and you. Bring your parents or a trusted adult, bring this page’s questions, and let a pediatric team earn a yes or a no. That’s not a brush-off; it’s the actual best route to the outcome you’re after.
References
Weghuber D, et al. Once-weekly semaglutide in adolescents with obesity (STEP TEENS), NEJM 2022. Hampl SE, et al. AAP Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity, Pediatrics 2023. Wegovy prescribing information (pediatric indication) — novo-pi.com; Zepbound label (adult-only) — pi.lilly.com. Locate studies via PubMed. Educational content for caregivers — not medical advice; decisions belong with your child’s clinicians.